Nautilus Biotechnology reported a third-quarter net loss of $15.6 million on October 27, compared with a $13.6 million loss a year earlier.
The protein-analysis technology company generated approximately $0.2 million in revenue, primarily from grant-funded activities and services provided through its Iterative Mapping Early Access Program.
Operating expenses rose 10% to $16.9 million, reflecting higher laboratory, professional-services and personnel costs, partly offset by lower facilities expenses. Cash, cash equivalents and investments totaled $114.3 million at September 30.
Nautilus said planned instrument availability remains in the middle of 2027. It is developing a pipeline intended to support twenty assays through mid-2028.
The release also described participation in the ARPA-H-funded SEEDS research consortium, with expected funding of up to $6 million. That is an anticipated amount, rather than revenue already received during the third quarter.
The company’s product and assay timelines remain development plans. The announcement does not establish approval of a clinical diagnostic test or demonstrated treatment benefits for patients.
Sources: Nautilus October 27 earnings release, distributed by GlobeNewswire and reproduced by StockTitan: https://www.stocktitan.net/news/NAUT/nautilus-biotechnology-reports-third-quarter-2026-financial-hiucyiijc3hj.html